Refractory Sarcoidosis Responding to Infliximab *
Authors:
- David S. WilkesDWDavid S. Wilkes
- Richard A. BurgettRBRichard A. Burgett
- Kenneth S. KnoxKKKenneth S. Knox
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Histoplasmosis after Treatment with Anti–Tumor Necrosis Factor-α TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-? therapyJournal of the American Academy of Dermatology, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial InfectionThe Journal of Immunology, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- The Gene Polymorphism of Tumor Necrosis Factor-β, But Not That of Tumor Necrosis Factor-α, Is Associated With the Prognosis of SarcoidosisChest, 2001
- Sarcoidosis and the heartCurrent Treatment Options in Cardiovascular Medicine, 2000
- Pentoxifylline in Treatment of SarcoidosisAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Pulmonary sarcoidosis: patterns of cytokine release in vitroEuropean Respiratory Journal, 1996
- Myocardial SarcoidosisChest, 1993